Clinical Evaluation Report for Medical Devices

Views:
 
     
 

Presentation Description

As per MEDDEV 2.7/1 Rev.4, Clinical Evaluation is a specialized robust method to collect, appraise and analyze clinical data related to a medical device and to interpret if there is satisfactory clinical information (evidence) to establish conformity with pertinent essential requirements for safety and performance when employing the medical device as per the manufacturer's instructions for use.

Comments

Presentation Transcript

slide 1:

CLINICAL EVALUATION REPORT An expert opinion…. Asha Meria Johnson http://www.i3cglobal.com 14 th August 2018

slide 2:

P a g e | 2 ABSTRACT A. CLINICAL EVALUTION and the NEED OF CLINICAL EVALUATION REPORT CER key documents for your CE Cerification This write up is to enlighten the medical device manufacturers to document Clinical Evaluation Report CER based on MEDDEV 2.7/1 Rev. 4 guidance. Here it explains how an evaluation is performed what information is required and how this information should be appraised analyzed and presented in the CER. The essentiality of an overall evaluation of the device is also highlighted with the precise focus on establishing that clinical data are evaluated in a systematic and objective way that the benefit risk profile is satisfactorily acceptable and that any gaps in clinical evidence are identified and addressed. As per MEDDEV 2.7/1 Rev.4 Clinical Evaluation is a specialized robust method to collect appraise and analyze clinical data related to a medical device and to interpret if there is satisfactory clinical information evidence to establish conformity with pertinent essential requirements for safety and performance when employing the medical device as per the manufacturers instructions for use. The evaluation should be based on a broad analysis of pre- and post-market clinical data relevant to the device under evaluation as well as any data disclosing about the devices claimed as equivalent or benchmark by the manufacturer. The requirements of clinical evaluation are imperative to all classes of medical devices. The evaluation should be true to the device under evaluation its specific properties and its intended purpose. Clinical evaluation is an obligation of the manufacturer and the CLINICAL EVALUATION REPORT CER where all the clinical evaluation processes are documented favorable and unfavorable is an essential aspect of the technical documentation for CE marking of the medical device in accordance with the requirements shown in Article 61 and Annex XIV of Official Journal of the European Union- Regulations Council Regulation 2017/745 of 5 April 2017 including a PMCF. Clinical Evaluation Report is one of the Heres What the Medical Device Manufacturers Need to Know

slide 3:

P a g e | 3 The manufacturer should take-charge of collecting clinical data of the CE marked Medical device in-use on humans with the objective of confirming the safety and performance as intended continuously during the expected lifetime of the device to confirm the continued acceptability of identified risks and to detect any emerging risks based on the real and correct clinical evidence. A PMCF plan and PMCF Evaluation Report should be maintained and when required preventive and/or corrective measures must be identified and the manufacturer should implement them. B. B1 STAGE 0: Scoping And The Clinical Evaluation Plan Scoping is defined based on the Essential Requirements that are vital to be addressed from a clinical context and the type and history of the device. The Clinical Evaluation Plan should include different aspects considering the stages in the lifecycle of the product. Device description Design features Risk Management documents current knowledge/ state of the art in the corresponding medical field data source inputs and types of data to be used in the clinical evaluation are included in all CERs whereas few aspects are specific to CERs before and after CE marking. VARIOUS STAGES OF CLINICAL EVALUATION

slide 4:

P a g e | 4 Before CE marking For CE marked devices Equivalent device data if claimed Any relevant changes such as: design changes changes to materials and manufacturing procedures changes to the information materials supplied by the manufacturer label IFU available promotional materials including accompanying documents possibly foreseen by the manufacturer or other claims and whether the claim of equivalence to an existing device is still appropriate Any specific clinical concerns that have newly emerged and need to be addressed PMS Data new PMS Plan including PMCF The demonstration of equivalence should be considered based on Technical Biological and Clinical characteristics and the equivalence identification should be provided with proper justification. B2 STAGE 1: Identifion Of Pertinent Data a Data that are generated and held by the manufacturer : pre-market clinical investigations clinical data generated from risk management activities and the PMS programmes PMCF Complaint reports Incident reports and so on.. relevant pre-clinical studies bench test reports- verification and validation data b Data derived from Literatures Clinical data relevant to the device under evaluation or to the equivalent device if equivalence is claimed Current knowledge/ the state of the art B3 STAGE 2: Appraisal of Pertinent Data The evaluators should appraise each individual document identified in Stage 1 in terms of its scientific validity relevance and weighting of its contribution to the evaluation of the clinical performance and safety of the device.

slide 5:

P a g e | 5 "The clinical evaluation report and the evidence for conformity assessment" B4 STAGE 3: Analysis Of The Data whereby conclusions are reached about in concurrence with Essential Requirements including ER1 ER3 ER6 on performance and safety of the device including its benefit-risk profile the contents of information and materials given by the manufacturer including the IFU Iabels of the device promotional materials including accompanying documents possibly aniticipated by the manufacturer residual risks and uncertainties or unanswered questions including on rare complications long-term performance safety under widespread use whether these are acceptable for CE-marking and whether they are required to be addressed during PMS. B5 STAGE 4: Clinical Evaluation Report CER Clinical Evaluation report CER has the summary and inferences of the evaluation of all the relevant clinical data documented or referenced in other parts of the Technical File documentation. relevant clinical data constitute the clinical Clinical Evaluation is a paramount aspect of CE Mark certification process because it guarantees that the evaluation of safety and performance of the device is based on adequate clinical evidence throughout the lifetime that the medical device is on the market. This continuous process enables manufacturers to handover the notified bodies and competent authorities with sufficient clinical evidence for the demonstration of conformity of the device with the Essential Requirements throughout its lifetime for example: for CE marking completion of post- market surveillance and reporting necessities or during surveillance processes.

slide 6:

P a g e | 6 C1. Clinical Evaluation During the Development of A Medical Device “The Clinical Evaluation Report is essential for initial CE- marking and it must be actively updated since that time onwards. It is conducted during the whole of the life cycle of a medical device as a continuous process” Mostly clinical evaluation is first performed during the development of a medical device in order to: a Interpret needs regarding clinical safety and clinical performance of the device - sufficient clinical evidence to establish conformity with the Essential Requirements covering clinical performance and clinical safety b Determine what data need to be generated for European market entry by carrying out a gap analysis - Post-market Surveillance PMS E.g. in post-market clinical follow- up studies PMCF Studies required under the medical device directives MEDDEV 2.12/2 . Generally these aspects include estimation of residual risks and uncertainties or unanswered questions such as rare complications uncertainties regarding long- term performance safety under wide-spread use EN ISO 14971:2012 c Find out whether clinical investigations are necessary and if so to define the study design EN ISO 14155:2011 d Decide desirable equivalence to an existing device thorough available clinical data RIGHT TIME FOR CLINICAL EVALUATION C.

slide 7:

P a g e | 7 The manufacturer should specify and substantiate the frequency at which the clinical evaluation needs to be actively updated. The clinical evaluation should be actively updated: 1. When the manufacturer collects new information from PMS that has the potential to change the current evaluation. As a manufacturer one should establish a PMS system with a well-defined scope and nature in line with the inteded pupose of the device that consistently monitors the clinical performance and clinical safety of the device as part of their quality management system. PMS should systematically generate new data such as safety reports results from published literatures registries PMCF studies and other data about device usage. Those data need to be evaluated for information that has a potential to change the evaluation of the benefit-risk profile and the clinical performance and clinical safety of the device. These data are required to be fed into the clinical evaluation files in a timely manner. In agreement with the Regulatory Directives the clinical evaluation and the clinical evaluation report must be actively updated with data obtained from post-market surveillance. 2. If no such information is received then CER should be updated: at least annually if the device carries serious risks or is not yet well established or every 2-5 years if the device is not expected to transmit serious risks and is well established a justification should be provided. When involvement of notified bodies is required updates are usually coordinated with the notified body. Usually they are lined up with the timetable for surveillance audits and the renewal of the certificates. C2. Updating the Clinical Evaluation Report "Clinical Evaluation can therefore lead to changes to the Manufacturers Risk Management Documents Instructions For Use IFU and PMS Activities ".

slide 8:

P a g e | 8 Clinical evaluation should be conducted by a well-qualified individual or a team and the evaluators should own experience and expertise in research methodology information management regulatory requirements medical writing proficiency of the technology of device under evaluation and its application diagnosis and management of the conditions intended to be diagnosed or managed by the device familiarity of medical alternatives medical care standards and technology e.g. specialist clinical expertise in the relevant medical specialty. In cases where the level of evaluator expertise may be less or different it should be recorded and properly justified. "DECLARATION OF INTEREST and CURRICULUM VITAE" of the ROLE OF CLINICAL EVALUATORS Few Points to Note D. EVALUATORS must be submitted with Clinical Evaluation Files to the Notified Body. “The evaluators should have 5-10 years of documented professional experience in the relevant field”.

slide 9:

P a g e | 9 WHAT THE NOTIFIED BODY WOULD CHECK FROM THE MANUFACTURERS CLINICAL EVALUATION REPORT E. device description and product specification intended purpose of the device classification proposed for the device pre-clinical evaluation data presented by the manufacturer risk analysis and risk management and alignment with the clinical evaluation report clinical evaluation process clinical evaluation report’s authors equivalence assessment – if data from equivalent is used clinical investigation plans and reports etc. F. a new CER with well tailored SOPs and templates for each stages updating your existing CER upgrading your CER to comply with the latest regulatory requirements MDD superseded by MDR assisting and training QA/RA team in your organization effectively to conduct Clinical evaluation including PMS PMCF Risk Management Files and so on. 1. MEDDEV 2.7/1 Revision 4. Clinical Evaluation: A Guide for Manufacturers and Notified Bodies Under Directives 93/42/EEC and 90/385/EEC2016 2. Official Journal of the European Union- Regulations Council Regulation 2017/745 of 5 April 2017 G. REFERENCES I 3 CONSULTING HELPS WITH EFFICIENT PREPARATION BUT NOT LIMITED:

slide 10:

P a g e | 10 We are a group of qualified and experienced Regulatory Affairs SpecialistsConsultants for Highly Regulated Markets such as Medical Devices Pharmaceuticals Cosmetics Food and Nutraceutical regulatory requirements working across the America Europe Middle East and Asia- Pacific. Despite the reach and capabilities of our offices we are large enough to guide fortune 500 companies and small enough to guide individually owned companies making us one of the most accepted regulatory service providers. No wonder the proof of our ability is answered by our massive number of customers which is increasing day by day mainly from client references I. The author would like to thank Mr. Soio George Lead Auditor and Project Head Medical Device EU USFDA Regulatory Compliance I 3 Consulting India for his guidance in preparing this article. J. Ms. Asha Meria Johnson B. Tech MS is a senior medical device regulatory consultant and Team Lead for Clinical Evaluation as per new MEDDEV 2.7/1 Rev. 4. She received her graduation from University of Calicut India and post-graduation from NJIT USA. Ms. Asha was completely engaged from the day of the release of MEDDEV 2.7/1 Rev. 4 in developing a practical approach plan towards submission of the Clinical Evaluation Report CER to various Notified Bodies on behalf customers across the globe. Her hard work and efforts have achieved the results today the team under her guidance and supervision has submitted successfully more than 35 CERs to various Notified Bodies. Readers may contact her at aji3cglobal.com 75 Executive Drive Suite 303 Aurora Illinois USA 60504. Telephone +1 630 696 1293 S8 JJ Park 4 Cross S.G Palya DRC Post Bangalore INDIA 560029. Telephone +91 994 591 2081 Contact Email: enquiryi3cglobal.com www.i3cglobal.com ABOUT I 3 CONSULTING H. ACKNOWLEDGEMENTS AUTHOR

authorStream Live Help